Our portfolio of completed projects includes, among others:
Dosimetry of ionizing radiation coming from Y-90 microspheres applied in radioembolization therapy
National Centre for Nuclear Research (NCNR) in cooperation with MIM and Institute of Nuclear Chemistry and Technology (INCT) developed the technology for Y-90 microspheres production with the use of sol-gel process. Produced spherical yttrium trioxide grains (30-50 pm in diameter) are then irradiated in the MARIA research reactor and in the course of nuclear reaction 89Y(n,x)90Y, Y-89 is transformed to radioactive Y-90. Physicochemical and radiometrie research show that such microspheres are promising medical materiał for radioembolization of liver malignancies.
Performed studies confirm the utility of PET/CT for quantitative assessment of distribution of the dose absorbed by the tumour tissue and its surroundings. Hence, we decided to carry out comprehensive research evaluating radiation dose distribution after Y-90 microspheres liver tumour radioembolization. Both tumour and healthy liver tissue absorbed dose will be assessed. The study objective was to evaluate the dose distribution in the liver after Y-90 SIRT.
Duration of the project: 2010.02.22 - 2022.08.21
Grant amount: 431 100.00 PLN
Badania przedkliniczne in vitro i in vivo nanozeolitu NA funkcjonalizowanego przeciwciałami anty-PSMA i znakowanego radioizotopem radu, jako potencjalnego związku dla celowanej terapii raka stercza
Głównym celem projektu były przedkliniczne badania in vitro i in vivo nowego związku – nanozeolitu NaA funkcjonalizowanego przeciwciałami anty-PSMA i znakowanego emiterem promieniowania α–radem 223 (223Ra) - jako potencjalnego radiofarmaceutyku dla celowanej terapii raka stercza. Osiągnięcia będące rezultatem projektu będą stanowiły istotny wkład w rozwój chemii jądrowej i radiacyjnej, a szczególnie dotyczących metod syntezy nowych związków, opartych na nanomateriałach znakowanych radionuklidami. Uzyskane rezultaty będą miały również istotny wkład w rozwój toksykologii nanomateriałów oraz radionuklidu 223Ra. Projekt realizowany w konsorcjum.
Duration of the project: 2015.06.01 - 2021.03.07
Grant amount: 166 200.00 PLN
Multivariate formulations of DOTATATE peptide as precursor for preparation of radiopharmaceuticals
Synthetic analogues of somatostatin, the regulatory peptide responsible for important functions of human body, are widely used in medicine. In addition, the radiolabelled octa-peptide analogues add to the diagnostic and therapeutic applications available for treatment of patients suffering from neuroendocrine tumors expressing somatostatin receptors with high density. Currently, the peptide known as DOTATATE (DOTA-Tyr3-octreotate), the synthetic analogue of somatostatin is used clinically when labelled with radionuclides. The goal of this project is to develop various pharmaceutical formulations of DOTATATE peptide, in the form of sterile freeze-dried kits which contain the appropriate mass of the peptide and appropriate excipients for each of the indications and each of the chemical form of the radionuclide. The composition of these kits will be optimized in order to assure the one step synthesis of the radiolabeled peptide, without the need of post-labelling purification and ready to be injected into the patient. The kits will be manufactured under GMP conditions supported by safety and stability data. Such kits will be offered to clinical partners providing them the easy access to the sterile peptide and excipient in the kit form. In this way the work load related to the preparation of the radiopharmaceutical at the hospital will be reduced and the requirements of Good Radiopharmacy Practice will be met at the reduced cost. In addition, the flexibility in preparing patient doses directly at the clinical site depending on the current indications for the individual patient in terms of the individually calculated dose will be assured. The goal of this project is to meet the demand of the national nuclear medicine as well as customers out of Poland. The presented approach addresses the modern theranostic and personalized medicine challenges.
Duration of the project: 2017.04.01 - 2020.03.31
Grant amount: 2 293 216.26 PLN
Pierwsza faza badania klinicznego z zastosowaniem nowego peptydowego analogu dla receptora CCK-2/gastryna dla zindywidualizowanej diagnostyki i terapii u pacjentów z wznową raka rdzeniastego tarczycy lub jego rozsiewem
Celem projektu było ustanowienie współpracy międzynarodowej w innowacyjnej dziedzinie celowanej terapii radionuklidowej aby dokonać oceny przydatności klinicznej wyselekcjonowanego nowego ligandu CP04 znakowanego 111In, jako radiofarmaceutyku wiążącego się z receptorami CCK-2/gastryny. Projekt wykorzystywał możliwości badawcze partnerów z Austrii, Grecji, Polski, Włoch, Słowenii i Niemiec. Wszyscy partnerzy posiadają duże doświadczenie i byli dobrze przygotowani do realizacji zadań projektu. Wyniki badań oceny bezpieczeństwa stosowania znacznika 111In-CP04 u chorych ze wznową raka rdzeniastego tarczycy lub jego rozsiewem oraz wyniki badań obrazowych prowadzone przez partnerów klinicznych projektu GRAN-T-MTC zachęcają do kontynuowania badań klinicznych już pod kątem skuteczności terapeutycznej, np. po wyznakowaniu peptydu CP04 izotopem promieniotwórczym emitującym promieniowanie beta, takim jak np. 177Lu. Partnerzy projektu przewidują występowanie o środki finansowe na kontynuowanie badań w ramach grantów badawczych.
Duration of the project: 2013.06.01 - 2018.08.31
Grant amount: 1 120 220.00 PLN
Nowatorski generator technetu (99Mo/99mTc) z mikroporowatym sorbentem na bazie chitozanu, wykorzystujący molibden 99Mo, do zastosowań w diagnostyce izotopowej
Głównym celem projektu było zaprojektowanie, skonstruowanie i zweryfikowanie funkcjonalności nowatorskiego generatora, zgromadzenie informacji związanych z jakościową i ilościową analizą chemicznych, radiochemicznych i radionuklidowych zanieczyszczeń, które może zawierać finalny produkt (eluat zawierający 99mTc) oraz przeprowadzenie badań dla zestawów farmaceutycznych, by spełniły one standardy Farmakopei Polskiej i Europejskiej. Projekt realizowany w konsorcjum.
Duration of the project: 2015.06.01 - 2018.05.31
Grant amount: 3 822 227.00 PLN
Radiopharmaceuticals for molecularly targeted medical diagnostics and therapy
In 2010, the Ministry of Health introduced a postgraduate specialization program in Radiopharmacy, which resulted in the need to educate specialized staff. The Interdisciplinary Doctoral Study: "Radiopharmaceuticals for molecularly targeted medical diagnostics and therapy" brought together the best specialists from many universities and research institutes, including: NCBJ and IChTJ (research institutes), the University of Warsaw and the Medical University of Warsaw (universities) as well as entities cooperating around the Center for the Design of Molecularly Targeted Radiopharmaceuticals, CERAD.
Duration of the project: 2018.10.01 – 2023.09.30
Grant amount: 775 445.00 PLN
Radiopharmaceuticals for molecularly targeted medical diagnostics and therapy
The ERA PerMed program (ERA-NET on Personalized Medicine) supported research related to modern methods of patient care (personalized medicine). The aim of the project was to select the most promising somatostatin receptor antagonist for clinical translation and to develop a pharmaceutical kit for NEN imaging in order to initiate a clinical feasibility study with assessment of diagnostic effectiveness.
Duration of the project: 2019.07.01 – 2023.06.30
Grant amount: 523 787.50 PLN
In 2013 - 2022, the activities of the Radioactivity Calibration Laboratory "Maintenance of the State Standard of the Radionuclide Activity Measurement Unit and the quality assurance system of calibrations performed" were carried out under four tasks.
Task No. 1 Maintenance of the State Standard of the Radionuclide Activity Measurement Unit
Work conducted included:
- Monitoring of measurement parameters and characteristics of the State Standard J.M.A.P.R.
- Technical supervision of the layouts of the State Model J. M. A. P. R.
- Replacement of worn-out electronic modules in the systems of the J.M.A.P.R. State Model.
Task No. 2 Transferring the unit of measure of radioactive activity with the help of the State Standard J. M. A. P. R.
Work conducted included:
- Measurements of radioactive solutions of various radionuclides,
- Measurements of radioactive sources of various types,
- Calibration of activity meters on behalf of external and internal customers.
Task No. 3 Comparative activity measurements
Work conducted included:
- International comparisons of radionuclide activity measurements,
- Organizing internal comparisons of activity measurements of radioactive solutions.
Task No. 4 Maintenance of the management system in accordance with PN-EN ISO/IEC 17025-2018-02.
Work conducted included:
- activities related to the operation of the management system (e.g., internal audits, management reviews),
- Preparation for PCA audit of the laboratory,
- Improving the competence of the Laboratory's staff
- Preparations for the introduction of EN 17034 (General requirements for the competence of manufacturers of reference materials)
Duration of the project: 2013 - 2022
Total funding value: 1 650 000.00 PLN
The research project, OPUS-17 (2019/33/B/ST5/02125), entitled “Novel polymeric nanocarriers as radioisotope transporters for oncology theranostics” concerted on the issues of nanoradiotherapy, which uses biologically active substances formed from the various nanoplatforms and the corresponding radioisotope, which, thanks to the emission of both beta and gamma radiation, are able to kill cancer cells while being detectable by appropriate imaging methods.
The nanoplatform proposed in the project was based on nanogels, that is, on polymer nanostructures obtained using a beam of accelerated electrons to which the radioisotope lutetium-177 or yttrium-90 was permanently attached.
Scheme illustrating the functionalization of nanogels, their radioisotope labelling and the selective binding of complete nanoparticles to tumour tissue.
In our project, for the first time, an actively targeted nanogel-based theranostic radioisotope delivery system was tested in vitro on prostate cancer tumour cells and a subcutaneous mouse model of prostate cancer.
The work carried out by the teams established in the three units resulted in 7 publications, 18 conference presentations and one PhD thesis submitted to the Lodz University of Technology.
Duration of the project: 2020.02.27 – 2024.02.26
Grant amount: 1 403 520.00 PLN
